New study tests best order of targeted drugs for tough colorectal cancer
NCT ID NCT04787341
First seen Feb 02, 2026 · Last updated May 15, 2026 · Updated 10 times
Summary
This study is for people with advanced colorectal cancer that has not responded to standard treatments. It compares two sequences of drugs: panitumumab followed by regorafenib, or the reverse order. The goal is to see which sequence helps patients live longer and controls the cancer better. About 214 adults will take part, and all must have a specific genetic type (RAS and BRAF wild-type) and have benefited from a prior anti-EGFR treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
U.O. Oncologia 2 Universitaria
Pisa, PI, 56126, Italy
Conditions
Explore the condition pages connected to this study.